Ginkgo Bioworks is the “Organism Company”, enabling the growth of biotechnology across diverse markets. Already valued at $15B, Ginko is not only giving biology a technological makeover; they are educating industries on the fact that “programming in the 21st century isn’t going to be computers — it’s biology.”
Here are ten facts you should know about Ginkgo Bioworks:
- Boston-based Ginkgo Bioworks has been programming cells since 2009.
- Soaring Eagle announced it would merge with Ginkgo in a deal that valued the Boston company at $15 billion.
- In 2020 Ginkgo brought in $77 million providing research services and covid-19 tests.
- Ginkgo Bioworks is proving that biology is a much more powerful manufacturing platform than most realised.
- Embodying the most significant trends in DNA science, it is believed that Ginkgo will become the Intel, Microsoft, or Amazon of biology.
- Ginkgo’s multibillion-dollar offering is a milestone in maturing synthetic biology from a science to a true industry.
- Ginkgo’s CEO Jason Kelly believes, “What computers did for information, biology will do for the physical world”.
- Ginkgo recently began trading on the New York Stock Exchange under the ticker symbol “DNA”. Their shares rose 6.6% on its first trading day, giving it a market cap of $2.6 billion.
- Ginkgo’s artisanal craft of manipulating biology is not driven by making products of its own but serves as a research platform for the entire synthetic biology industry.
- Ginkgo plans to close new cell programs and has so far added 30 programs this year.